BRAIN Initiative: Reagent Resources for Brain Cell Type-Specific Access and Manipulation to Broaden Distribution of Enabling Technologies for Neuroscience (U24 Clinical Trial Not Allowed) | RFA MH 21 180

Frequently Asked Questions (FAQs)

What is this funding opportunity about?

This NIH BRAIN Initiative funding opportunity (RFA-MH-21-180) supports the creation or strengthening of production and distribution facilities that can reliably manufacture and disseminate specialized reagents used to access and manipulate specific brain cell types. The aim is to move promising tools beyond small pilot efforts into scaled, standardized, community-facing resources that many neuroscience labs can obtain and use.

What is the main goal of the program?

The main goal is to build operational capacity (manufacturing, quality systems, scaling, and distribution) so that brain cell type-specific reagents can be produced consistently and made broadly available to the neuroscience community, rather than remaining limited to small-scale pilot production.

What NIH initiative is sponsoring this FOA?

The sponsor is the National Institutes of Health (NIH) under the BRAIN Initiative.

What is the funding mechanism and why does it matter?

The award mechanism is a U24 cooperative agreement. This matters because it implies substantial NIH programmatic involvement, and funded groups are expected to coordinate closely with NIH and with other related BRAIN Initiative projects. The program is structured around coordinated infrastructure, shared standards, and community distribution.

Are clinical trials allowed under this FOA?

No. Clinical trials are not allowed under this funding opportunity.

Is this FOA primarily for discovering brand-new reagents?

No. Rather than primarily funding discovery of brand-new reagents, this FOA emphasizes operational capability: setting up or expanding facilities, implementing robust quality systems, scaling production, and distributing reagents that originate from the BRAIN Initiative Armamentarium pilot resource projects.

What are the BRAIN Initiative Armamentarium pilot resource projects?

The Armamentarium pilot resource projects are developing brain cell type-specific access and manipulation reagents across vertebrate species. In this FOA, U24 awardees are positioned as the manufacturing and distribution arm that helps those tools reach widespread use.

What kinds of reagents are envisioned for manufacturing and distribution?

The reagents envisioned include, but are not limited to, viral vectors, nucleic acid constructs, and nanoparticles engineered for selective targeting of defined brain cell types.

What are these reagents used for in neuroscience research?

These tools enable researchers to label, record from, perturb, or otherwise manipulate particular neuronal or glial populations with high precision. They are central to modern systems and circuit neuroscience because they provide selective access to specific brain cell types.

What research contexts are the distributed reagents expected to support?

The FOA highlights use in experimental animals as well as in ex vivo human tissue and cells. This underscores the expectation that distributed reagents should be practical and broadly compatible with multiple research contexts while maintaining specificity and performance.

What does "scaled, standardized, community-facing resources" mean in practice?

Based on the FOA description, it means moving from limited pilot production to reliable, higher-throughput manufacturing and distribution that the broader community can access, with standardized processes and consistent reagent quality suitable for widespread adoption by many labs.

What types of activities are awardees expected to perform beyond manufacturing?

A key expectation is active collaboration and service to the community. This typically implies community-oriented functions such as standard operating procedures, documentation, best-practice guidance, user support, feedback loops for reagent performance, and continual improvement to keep tools reliable and usable as they scale to many labs.

Is collaboration required?

Yes. Awardees will work with other BRAIN Armamentarium awardees to manufacture and distribute reagents, and they are also expected to interact with the wider neuroscience community to optimize use of the new resources.

Which institutions are the focus of this FOA?

The focus is on building capacity at minority-serving institutions (MSIs) and IDeA-eligible institutions, with the broader goal of expanding who can serve as a hub for enabling neuroscience technologies and improving access for the entire research community.

What types of organizations are eligible to apply?

Eligibility is broad in the general NIH sense, including various levels of government, higher education institutions, nonprofits, for-profit organizations (other than small businesses), and small businesses. However, this FOA is specifically intended to establish facilities at MSIs and IDeA-eligible institutions.

Does the FOA mention specific categories often associated with MSI status?

Yes. The opportunity explicitly mentions categories including HBCUs, Hispanic-serving institutions, Tribally Controlled Colleges and Universities, Alaska Native and Native Hawaiian Serving Institutions, and AANAPISI institutions. It also references faith-based or community-based organizations, regional organizations, and U.S. territories or possessions.

Can a foreign institution apply?

No. Foreign institutions are not eligible to apply.

Are non-U.S. components of U.S. organizations eligible?

No. Non-U.S. components of U.S. organizations are not eligible under this FOA.

Are any foreign activities allowed at all?

Yes, foreign components are allowed as defined by the NIH Grants Policy Statement. This indicates that certain project elements may involve foreign activities or collaborations under NIH rules, even though the applicant organization itself must be domestic and eligible.

What is the role of NIH in a U24 cooperative agreement for this program?

The FOA states that NIH will have substantial programmatic involvement. This implies that awardees should expect to coordinate closely with NIH and align operations with program goals such as shared standards, coordinated infrastructure, and broad community distribution.

What is the broader impact this FOA is trying to achieve?

The FOA connects infrastructure-building at MSIs and IDeA-eligible institutions with expanding who can serve as a hub for enabling neuroscience technologies, and improving access to these specialized reagents for the entire research community.

What is the listed closing date for the opportunity?

The original closing date listed is 2023-10-24.

How is this opportunity categorized?

The opportunity is categorized under a discretionary grant program.

What activity areas are associated with this opportunity?

The activity areas span education, health, income security, and social services, and the FOA notes multiple CFDA numbers associated with NIH neuroscience and mental health related programs.

Where do the reagents being scaled up come from?

The FOA emphasizes distributing reagents that originate from the BRAIN Initiative Armamentarium pilot resource projects, positioning the U24 awardees as the scaled manufacturing and distribution channel for those tools.